Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vincera Pharma, Inc.

0.6206
+0.00130.21%
Mar 21 13:19 EST
Volume:151.79K
Turnover:93.91K
Market Cap:1.39M
PE:-0.04
High:0.6480
Open:0.6010
Low:0.6000
Close:0.6193
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
More
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h

Vincerx Pharma Q3 Basic EPS USD -0.17

THOMSON REUTERS
·
12 Nov 2024

Vincerx Pharma Q3 Operating Expenses USD 7.793 Million

THOMSON REUTERS
·
12 Nov 2024

Press Release: Vincerx Pharma Reports Third Quarter 2024 Financial Results

Dow Jones
·
12 Nov 2024

Vincerx Pharma Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
08 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
08 Nov 2024

Vincerx Pharma Is Maintained at Outperform by Leerink Partners

Dow Jones
·
08 Oct 2024

Vincerx Pharma Inc : Leerink Partners Cuts Target Price to $2 From $4

THOMSON REUTERS
·
08 Oct 2024

Vincerx Pharma Reports 'Positive' Initial Clinical Data on Leukemia Drug; Shares Jump After Hours

MT Newswires Live
·
07 Oct 2024

BRIEF-Vincerx Reports Positive Initial Clinical Data From Ongoing Vip943 Phase 1 Dose-Escalation Study And Provides Pipeline And Corporate Updates

Reuters
·
07 Oct 2024

Vincerx Reports Positive Initial Clinical Data From Ongoing Vip943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates

THOMSON REUTERS
·
07 Oct 2024

Vincerx Pharma Inc - Expected Cash Runway Into Early 2025

THOMSON REUTERS
·
07 Oct 2024

Vincerx Pharma Inc - Vincerx Focusing Resources on Continued Development of Vip943

THOMSON REUTERS
·
07 Oct 2024

Vincerx Pharma Inc - Anticipates Providing Another Data Update on Ongoing Phase 1 Vip943 Study by End of Year.

THOMSON REUTERS
·
07 Oct 2024

Vincerx Pharma Inc - Vip943 Demonstrates Promising Safety and Tolerability and Achieves Two Complete Responses to Date in Phase 1 Dose-Escalation Study

THOMSON REUTERS
·
07 Oct 2024

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."